Table 4.

ORs (95% CI) for TP53polymorphisms in CIN3+/persistent HPV cases compared with random controls, stratified by HPV type (oncogenic HPV, HPV16, HPV18, and nononcogenic HPV), and adjusted for age

HPV type
TP53 polymorphismOncogenic* (599 cases/74 controls)HPV16 (96 cases/21 controls)HPV18 (27 cases/8 controls)Nononcogenic (268 cases/95 controls)
rs12951053
    TT1.01.01.01.0
    GT2.1 (1.1-4.1)0.86 (0.26-2.8)1.6 (0.26-9.7)1.4 (0.79-2.5)
    GGNANANA1.5 (0.32-7.5)
Ptrend0.010.950.480.23
rs1042522 (Pro72Arg)
    GG1.01.01.01.0
    CG1.8 (1.1-3.1)1.2 (0.41-3.3)6.7 (0.62-72.9)1.5 (0.92-2.6)
    CC3.1 (1.1-9.0)1.5 (0.16-14.3)1.4 (0.11-17.3)2.1 (0.85-4.9)
Ptrend0.010.680.330.04
rs1642785
    GG1.01.01.01.0
    CG1.3 (0.78-2.2)0.33 (0.1-1.1)3.7 (0.60-23.2)1.4 (0.85-2.3)
    CC4.6 (1.1-19.7)0.68 (0.1-7.0)NA2.0 (0.77-5.1)
Ptrend0.030.170.090.08
  • NOTE: ORs and 95% CIs are adjusted for age. All CIN3+ cases were included, regardless of HPV testing.

  • Abbreviation: NA, not applicable.

  • * Oncogenic HPV types included HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68. HPV testing results were available for 65% of cases.

  • Nononcogenic HPV types included HPV types 6, 11, 32, 40, 53, 54, 55, 61, 62, 67, 70, 71, 72, AE10 (74 variant), 81, 83, 84, 85, 89.